HAE
Haemonetics (HAE) Stock Valuation
Review Haemonetics (HAE) valuation with server-rendered company data, supporting context and links to related investor research.
- Price to earnings
- 53.14
- Price to book
- 3.21
- Dividend yield
- 0%
- Return on equity
- 0%
- BTI fair market cap
- 2.46 B
- Premium or discount
- 69.05%
- Market cap
- 4.93 B
Haemonetics (HAE) Stock Valuation research
The Haemonetics valuation page presents the available multiples, profitability measures and BTI fair-value context for HAE. Valuation should be compared with the company's growth, margins, balance sheet and relevant peers rather than judged by one multiple.
A premium may reflect stronger expected growth or quality, while a discount can reflect risk or weak expectations. Neither condition alone establishes that a stock is attractive or unattractive.